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ORIGINAL ARTICLE
A multi-subunit Chlamydia vaccine inducing
neutralizing antibodies and strong IFN-γ+ CMI
responses protects against a genital infection
in minipigs
Sarah Bøje1,2, Anja Weinreich Olsen2, Karin Erneholm1,2, Jørgen Steen Agerholm1, Gregers Jungersen3,
Peter Andersen2 and Frank Follmann2
Chlamydia is the most widespread sexually transmitted bacterial disease and a prophylactic vaccine is highly needed. Ideally,
this vaccine is required to induce a combined response of Th1 cell-mediated immune (CMI) response in concert with
neutralizing antibodies. Using a novel Göttingen minipig animal model, we evaluated the immunogenicity and efﬁcacy of a
multi-subunit vaccine formulated in the strong Th1-inducing adjuvant CAF01. We evaluated a mixture of two fusion proteins
(Hirep1 and CTH93) designed to promote either neutralizing antibodies or cell-mediated immunity, respectively. Hirep1 is a
novel immunogen based on the variant domain (VD) 4 region from major outer membrane protein (MOMP) serovar (Sv) D,
SvE and SvF, and CTH93 is a fusion molecule of three antigens (CT043, CT414 and MOMP). Pigs were immunized twice
intramuscularly with either Hirep1+CTH93/CAF01, UV-inactivated Chlamydia trachomatis SvD bacteria (UV-SvD/CAF01) or
CAF01. The Hirep1+CTH93/CAF01 vaccine induced a strong CMI response against the vaccine antigens and high titers of
antibodies, particularly against the VD4 region of MOMP. Sera from Hirep1+CTH93/CAF01 immunized pigs neutralized
C. trachomatis SvD and SvF infectivity in vitro. Both Hirep1+CTH93/CAF01 and UV-SvD/CAF01 vaccination protected pigs
against a vaginal C. trachomatis SvD infection. In conclusion, the Hirep1+CTH93/CAF01 vaccine proved highly immunogenic
and equally protective as UV-SvD/CAF01 showing promise for the development of a subunit vaccine against Chlamydia.
Immunology and Cell Biology (2016) 94, 185–195; doi:10.1038/icb.2015.79
Chlamydia is the most common bacterial sexually transmitted disease,
and worldwide, more than 100 million people are infected each year
with the urogenital serovars (Svs) of Chlamydia trachomatis.1 The
infection is often without symptoms and therefore left undiagnosed
and untreated. This increases the risk of developing severe complica-
tions, such as pelvic inﬂammatory disease and infertility.2 At present,
the main public intervention to reduce the incidence of genital
chlamydia is routine screening programs, which until now has been
largely unsuccessful,1 and development of a vaccine against chlamydia
is therefore an international priority.3
In humans, repeated chlamydial infections are common, although
natural immunity can develop.4 The exact immune correlates of
protection are unknown, however, it is generally accepted that both
humoral and cell-mediated immune (CMI) responses are important.
The presence of antibodies in cervical secretions of women correlates
with lower bacterial shedding,5 and interferon (IFN)-γ-positive
responses in peripheral blood mononuclear cells (PBMCs) stimulated
with cHsp60 correlates with a decreased risk of acquiring a subsequent
chlamydial infection.6 Studies in mice consistently identify a key
protective role for CD4+ Th1 cells and the cytokine IFN-γ.7–9
The protective role of antibodies is more multifaceted and ranges
from direct bacterial neutralization10 to accelerating CMI through
Fc-mediated uptake in antigen-presenting cells.11
Vaccines based on intact Chlamydia bacteria demonstrate that
protection can be achieved both in non-human primates and in
clinical trials.12,13 However, protection seems to be Sv-speciﬁc13 and a
whole-cell vaccine may potentially generate unwanted responses and
lead to pathology,14 emphasizing the need for a broadly protective
subunit vaccine. Vaccine research efforts have led to the identiﬁcation
of a large number of antigens with signiﬁcant protective efﬁcacy.15–18
Efforts to identify a target for neutralizing antibodies have mainly
focused on major outer membrane protein (MOMP), but the complex
structure of the protein has complicated its use as a vaccine
antigen.19,20
1Section of Veterinary Reproduction and Obstetrics, Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C,
Denmark; 2Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen S, Denmark and 3Immunology and Vaccinology,
National Veterinary Institute, Technical University of Denmark, Frederiksberg C, Denmark
Correspondence: Dr F Follmann, Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S,
Denmark.
E-mail: frf@ssi.dk
Received 22 April 2015; revised 14 July 2015; accepted 29 July 2015; accepted article preview online 13 August 2015; advance online publication, 22 September 2015
Immunology and Cell Biology (2016) 94, 185–195
& 2016 Australasian Society for Immunology Inc. All rights reserved 0818-9641/16
www.nature.com/icb
In addition to identifying the right antigens, vaccine-induced
immunity to Chlamydia highlights the challenge of identifying a
clinically relevant delivery system that would induce a strong Th1
response, antibodies and long lived memory.21 The CAF01 adjuvant
has demonstrated potent induction of CMI and humoral immunity
with several chlamydial antigens in mouse models.17,22 Importantly,
the adjuvant has also been tested in phase I trials23,24 with an excellent
safety proﬁle and is a promising adjuvant for a recombinant vaccine
against Chlamydia.
So far, most Chlamydia vaccine research has been carried out in
mice.15–17 To move promising vaccine candidates closer to a clinical
trial, there is a need for testing in animal models with closer
resemblance to humans than rodents. Pigs are immunologically
and physiologically in many ways comparable with humans,25–27
Table 1 Design of study
No of pigs Immunization groups Timepoint
Week 0 Week 3
Week 7 Day 0
post infection Day 12 pi
5 CAF01 First
immunization
Second
immunization
Infection Killing
5 10 μg Hirep1+CTH93/CAF01
5 100 μg Hirep1 +CTH93/CAF01
4 125 μg UV-SvD/CAF01
Abbreviation: pi, post infection.
Figure 1 Characterization of vaccine-induced immune responses. Pigs were intramuscularly immunized at week 0 and 3 with 10 μg (n=5) or 100 μg (n=5)
Hirep1+CTH93/CAF01 or UV-SvD/CAF01 (n=4). Blood samples and vaginal swabs were taken at weeks 0, 3 and 7 to evaluate CMI and humoral responses.
(a) PBMCs were restimulated in vitro with Hirep1, CTH93 and UV-SvD. For each pig, the mean IFN-γ of triplicate culture wells was calculated and the bars
represent the median± interquartile range within a group. (b) Serum IgG and (c) vaginal IgG titers speciﬁc for Hirep1, CTH93 and UV-SvD were analyzed in
duplicates and the mean were calculated. Bars represent medians± interquartile range within a group. Statistical difference was calculated using the
Friedman test followed by Dunn’s multiple comparison test, *Po0.05, **Po0.01.
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facilitating the evaluation of vaccine immunogenicity in this animal
species. Importantly, a previous study has demonstrated that pigs are
susceptible to genital C. trachomatis infection.28
We recently constructed a novel recombinant version of MOMP,
based on the variant domain (VD)4 regions of SvD, SvE and SvF
(Hirep1) that induces high titered neutralizing antibodies, covering Svs
causing up to 90% of all infections and showing for the ﬁrst time that
vaccine-induced antibodies can control Chlamydia infections.29 In the
present study, we combine Hirep1 with a recombinant fusion
molecule CTH93, consisting of previously identiﬁed antigens;
CT043,17,30,31 MOMP (CT681)amino acid (aa)34-371
15–17,31 and
CT414aa605-840. CTH93 represents a broad epitope repertoire covering
both T- and B-cell epitopes, but lacks the ability to induce neutralizing
antibodies. In the current study, we evaluate the immunogenicity and
efﬁcacy of Hirep1+CTH93 formulated in CAF01 in Göttingen
minipigs.
RESULTS
The Hirep1+CTH93/CAF01 vaccine is highly immunogenic
Göttingen minipigs were immunized with a mixture of Hirep1
(comprising the VD4 domain of MOMP SvD, SvE and SvF) and
CTH93 (consisting of MOMP SvDaa34-371, CT043 and CT414aa605-840)
(Supplementary Figure 1) formulated in CAF01, with the purpose of
inducing neutralizing antibodies and strong T-cell responses.
Throughout the study, the Hirep1+CTH93/CAF01-induced responses
were compared with immune responses in UV-SvD/CAF01-
immunized pigs. Nineteen sexually mature minipigs were randomly
allocated into four immunization groups receiving 10 μg Hirep1
+CTH93/CAF01, 100 μg Hirep1+CTH93/CAF01, 125 μg UV-SvD/
CAF01 or CAF01 alone (Table 1). The pigs were immunized twice
in the neck muscles spaced with an interval of 3 weeks.
At week 0, 3 and 7, PBMCs were isolated from blood samples and
restimulated with the recombinant, vaccine antigens (Hirep1 and
CTH93) and with UV-SvD. After immunizations, Hirep1+CTH93/
CAF01-immunized groups showed signiﬁcant higher levels of IFN-γ
against Hirep1 and CTH93 compared with week 0 (Figure 1a).
Furthermore, the Hirep1+CTH93/CAF01 vaccine-induced CMI
responses were able to recognize UV-SvD, comparable with the levels
in UV-SvD/CAF01-immunized pigs.
To examine humoral immune responses, we collected sera and
vaginal swabs at week 0, 3 and 7. Both groups of pigs immunized with
Hirep1+CTH93/CAF01 had signiﬁcant levels of speciﬁc IgG in serum
(Figure 1b). The Hirep1+CTH93/CAF01-generated antibodies were
able to recognize the surface of UV-SvD, comparable with the levels
Figure 2 Mapping of T-cell epitopes after two immunizations in peptides (20-mer with 10 aa overlap) covering MOMP. PBMCs from (a) UV-SvD/CAF01
(n=4)- and (b) Hirep1+CTH93/CAF01 (n=10)-immunized pigs were restimulated in vitro with individual peptides (see Supplementary Table 1 for
sequences), spanning the MOMP SvD protein including SvE- and SvF-speciﬁc peptides in VD4. The graph is based on the mean IFN-γ value of duplicate
culture wells for each pig. The box indicates the 25th and the 75th percentile within the group, the horizontal line within a box represents the median, and
whiskers indicate min to max values. The sequence of constant sequences (CS) and VDs of MOMP is depicted below the graphs.
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induced in UV-SvD/CAF01-immunized pigs. Importantly, high titers
of vaccine-speciﬁc antibodies were also detected on the vaginal mucosa
(Figure 1c), reﬂecting transudation of serum into the genital tract in
the vaccinated pigs.
Hirep1+CTH93/CAF01 vaccination primarily induces T-cell
epitopes in the VD4 regions of MOMP from SvD, SvE and SvF
As there were no signiﬁcant differences between immune responses in
the groups receiving 10 and 100 μg Hirep1+CTH93/CAF01 (shown in
Figure 1), we decided to pool results from the two hybrid vaccine
groups for further analysis.
T-cell responses against the individual vaccine components were
characterized in more detail by stimulating with peptide pools
representing the individual vaccine components (Hirep1, MOMP
SvD, CT043 and CT414aa605-840) (Supplementary Figure 2). In general,
peptide pools representing the individual vaccine components, Hirep1,
MOMP SvD and CT043, were frequently and strongly recognized in
Hirep1+CTH93/CAF01-vaccinated pigs with levels of IFN-γ signiﬁ-
cantly different from naïve controls. In contrast, recognition of
CT414aa605-840 was low. UV-SvD/CAF01-immunized pigs did not
respond to peptide pools representing any of the vaccine antigens.
To localize T-cell epitopes in the individual components, PBMCs were
stimulated with individual 20-mer peptides with 10 aa overlap
(Supplementary Tables 1–3) covering the vaccine antigen components
(Hirep1 and MOMP SvD (Figure 2), CT043 and CT414aa605-840
(Supplementary Figure 3A). For MOMP, peptides covering full length
MOMP SvD were used. To cover the Hirep1 fusion construct,
peptides covering VD4 of SvE and SvF were included (SvE peptide
30–31, SvF peptide 27–32), when they differed in sequence from VD4
of MOMP SvD. In agreement with the low recognition of the MOMP
SvD peptide pools in the UV-SvD/CAF01-vaccinated group, only few
T-cell epitopes were detected (Figure 2a). In Hirep1+CTH93/CAF01-
immunized pigs, multiple T-cell epitopes were identiﬁed throughout
MOMP, both in constant and variable domains (Figure 2b). T-cell
epitopes were predominantly identiﬁed in a region of MOMP (peptide
25–35) comprising conserved sequences and VD4 of SvD, SvE and
SvF. Especially, peptide 30 of SvD and SvE, and peptide 28 and 32 of
SvF were frequently recognized. The recognition of the Sv-speciﬁc
peptides, especially SvF peptide 27–32, may indicate a Hirep1-induced
T-cell response. In Hirep1+CTH93/CAF01-immunized pigs, the
epitopes in CT043 and CT414aa605-840 (Supplementary Figure 3A)
were recognized by most pigs in peptides 10–13 and 18–23,
Figure 3 Mapping of B-cell epitopes after two immunizations in peptides (20-mer with 10 aa overlap) covering MOMP. The mapping was performed with
sera from (a) UV-SvD/CAF01 (n=4)- and (b) Hirep1+CTH93/CAF01 (n=10)-immunized pigs. Serum antibody recognition of overlapping peptides
(see Supplementary Table 1 for sequences) spanning MOMP SvD, and SvE- and SvF-speciﬁc sequences in VD4. The graph is based on the mean OD value
of duplicates for each pig. The box indicates the 25th and the 75th percentile within the group, the horizontal line within a box represents the median, and
whiskers indicate min to max values. The sequence of CSs and VDs of MOMP is depicted below the graphs.
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respectively, whereas the CT043 and CT414aa605-840 peptide
recognition in UV-SvD/CAF01-immunized pigs was low (data not
shown).
Strong antibody recognition of surface-exposed and Sv-speciﬁc
regions of MOMP
To characterize antibody recognition of vaccine components, epitope
mapping of linear B-cell epitopes was performed post immunizations
(week 7) by evaluating serum antibody recognition of overlapping
peptides (20-mer with 10 aa overlap) (Supplementary Tables 1–3)
covering the individual vaccine components (MOMP SvD and Hirep1
(Figure 3), CT043 and CT414aa605-840 (Supplementary Figure 3B). In
UV-SvD/CAF01-immunized pigs, the antibody recognition of MOMP
was clustered, largely consistent with the surface-exposed VD sequences
(Figure 3a), especially VD3 and VD4. The pattern was similar in
Hirep1+CTH93/CAF01-immunized pigs (Figure 3b), but additionally,
transmembrane and periplasmic regions adjacent to VD3 and VD4
were recognized. This demonstrates broader antibody recognition
owing to presentation of more B-cell epitopes in the hybrid vaccine.
Recognition of non-Hirep1 peptides in MOMP SvD (peptide #o25)
indicates a CTH93-induced response. In both vaccine groups, peptide
30 of SvD, SvE and SvF was strongly recognized. In addition, peptides
of CT043 (peptide 1–2, 6–7 and 14–16) and CT414aa605-840 (peptide 1,
4, 14–16 and 22) were strongly recognized in Hirep1+CTH93/CAF01-
immunized pigs (Supplementary Figure 3B) compared with low
responses in the UV-SvD/CAF01-vaccinated group (data not shown).
Immune sera neutralizes SvD and SvF infectivity in vitro
Peptide 30 in MOMP contains the TLNPTIAG sequence
(Supplementary Table 1) associated with induction of neutralizing
antibodies. As shown in Figure 3, peptide 30 in MOMP SvD, SvE and
SvF was strongly recognized by serum antibodies from both
Hirep1+CTH93/CAF01 and UV-SvD/CAF01 immunized pigs. Further
analysis of sera recognition of peptide 30 in MOMP SvD demonstrated
high end point titers in both Hirep+CTH93/CAF01 (median: 125.000,
interquartile range: 125.000–125.000)- and UV-SvD/CAF01 (median:
125.000, interquartile range: 35.000–500.000)-immunized pigs.
To evaluate the neutralizing abilities of the antibodies, an in vitro
neutralization assay32 was performed using sera collected post
immunizations (week 7) and tested against SvD and SvF. We observed
strong and broadly neutralizing capacity against SvD and SvF of sera
from all individual animals in the Hirep1+CTH93/CAF01 group
(Figure 4). Sera from pigs immunized with UV-SvD/CAF01 also
had the capability to neutralize SvD and SvF, however, within this
group, we observed great variability in responses ranging from no
neutralization to as high as observed in the Hirep1+CTH93/
CAF01 group.
Hirep1+CTH93/CAF01 vaccination protects against vaginal
infection
To evaluate the protective efﬁcacy of the vaccines, the pigs were estrus
cycle synchronized and intravaginally inoculated with 3.9× 109
inclusion forming units (IFUs) during estrus at week 7, and vaginal
swabs were taken at days 3, 5, 7 and 12 pi. The levels of chlamydial
16S rRNA were quantiﬁed by qPCR, and for comparison at day 3 pi,
vaginal swabs were also cultured on McCoy cells to detect the number
of IFUs (Figure 5). At day 3 pi, levels of chlamydial DNA and IFUs
were signiﬁcantly decreased in Hirep1+CTH93/CAF01-immunized
pigs compared with controls. However, as control pigs rapidly cleared
Figure 4 In vitro neutralization of C. trachomatis SvD and SvF. Serial dilutions of sera from Hirep1+CTH93/CAF01 (n=10)- and UV-SvD/CAF01
(n=4)-immunized pigs were incubated with SvD or SvF. The sera-bacteria solutions were transferred to HaK cells, and IFUs were ﬁxed, stained and counted.
Results are given as the neutralization titer of each immunized pig in relation to pooled sera from naïve controls (n=5). Each dot represents the mean of
duplicate wells, and a connecting line between the dilutions is shown.
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the infection, this protection was only detected at day 3 pi, after which
the levels were comparable (data not shown).
Immune responses post infection demonstrate signiﬁcant CMI
recall in vaccinated pigs
Evaluation of antibody responses after the infection was carried out in
sera and vaginal swabs against Hirep1, CTH93 and UV-SvD, and
results revealed no signiﬁcant sera and vaginal antibody recall
responses in vaccinated pigs (data not shown). Evaluation of CMI
responses post challenge was carried out in PBMCs collected at days 0
and 7 pi. CMI responses to the infection alone, represented by pigs
immunized with adjuvant alone (CAF01 controls) (Figure 6a),
demonstrated UV-SvD-speciﬁc IFN-γ responses at day 7 pi
(P= 0.0625), and responses against Hirep1 were also increased
(P= 0.0625). In Hirep1+CTH93/CAF01-vaccinated pigs (Figure 6b),
the CMI recall responses against both UV-SvD, Hirep1 and
CT414aa605-840 was signiﬁcantly increased, whereas the responses
against peptide pools of CT043 and MOMP SvDaa34-371 were only
modestly elevated. In contrast, the UV-SvD/CAF01 group only
responded against UV-SvD (Figure 6c).
DISCUSSION
Considerable data support the concept that an ideal Chlamydia vaccine
would need to elicit both humoral and CMI-based immune
responses.33,34 Ideally, efﬁcient mucosal neutralizing antibodies reduce
initial infectious bacterial load and once intracellular, the bacteria are
eliminated by a strong CMI-driven response. Trachoma studies in
NHPs and clinical trials in the 1960s using whole-cell vaccines were at
least partially successful in reducing conjunctival infection, but
protection was short-lived14 and Sv-speciﬁc;13 suggesting that the
infection can be controlled by a vaccine if long-term protection and
broad Sv coverage are established.
In the present study, we evaluate a multi-subunit vaccine containing
Hirep1+CTH93/CAF01. CTH93 is a fusion molecule consisting of
three antigens identiﬁed in our discovery program: CT414aa605-840
(unpublished), CT043 and MOMP SvDaa34-371.
17,31,35 Hirep1 is a
molecularly designed version of MOMP that induces broadly neu-
tralizing antibodies targeting the most prevalent Svs.29 To induce a
combined humoral and CMI response, we used the CAF01 adjuvant,
which has previously been shown to induce both antibody and
Th1 cell responses36 and has passed clinical safety evaluation.24 The
vaccines were administered intramuscularly twice, and, regardless of
dose (10 or 100 μg), induced highly speciﬁc serum and vaginal IgG
levels and strong CMI responses (Figure 1). Individual antigens
were recognized with a broad spectrum of B- and T-cell epitopes
presented.
Epitope mapping of CT043 and CT414aa605-840 demonstrated broad
B-cell recognition for both, whereas especially CT043 induced a strong
and broad T-cell epitope recognition pattern. CT414aa605-840 was
initially identiﬁed in our laboratory in a phage display assay probed
with sera from human patients diagnosed with a genital infection
(unpublished data) and the full length protein has been shown to react
with sera from infected patients,35 indicating that the antigen is a
B-cell target in infected humans. CT043 was originally identiﬁed as a
frequent human T-cell antigen30,31,37 and has later been shown to
elicit CD4 T-cell-mediated protection against genital infections in
mice, and CT043-speciﬁc antibodies recognize the chlamydial
surface.17
MOMP contains numerous human T-cell epitopes,38,39 conse-
quently aa34–371 of MOMP SvD was included in CTH93 to expand
the overall T-cell repertoire. T-cell epitope mapping in MOMP
(Figure 2) demonstrated that in pigs, T-cell epitopes are present
throughout MOMP with frequently recognized peptides in peptide
25–35 including constant sequence IV, which is known to contain
several human T-cell epitopes.38 In mice, Hirep1 has been shown to
induce both antibody and T-cell responses to Sv-speciﬁc and
conserved epitopes.29 Hirep1-vaccinated mice are protected against
genital challenge with C. trachomatis SvD and SvF, and this protection
is mediated by broadly neutralizing antibodies in concert with a CMI
response. Interestingly, we observe multiple vaccine-induced T-cell
epitopes recognized in the VD4 region. In particular, peptide 30 in
MOMP SvD and SvE containing the conserved neutralizing antibody
epitope TLNPTIAG was strongly and frequently recognized.
Noticeably, also Sv-speciﬁc regions covered in peptides 28, 31 and
32 were recognized. This broad and signiﬁcant T-cell response
covering all Svs represented in the vaccine was unique for the
Hirep1+CTH93/CAF01-immunized pigs and not found in the
UV-SvD/CAF01 group. Importantly, this Hirep1-speciﬁc T-cell
response was signiﬁcantly boosted following the infection (Figure 6),
indicating a strong T-cell recall response targeting the VD4 region
in MOMP during infection. This broadens the immunological
importance of the VD4 region and suggests that beside a clear target
for antibodies, this region is also a possible target for T cells during
infection. Karunakaran et al.40 recently suggested that surface proteins,
including MOMP, are enriched among the Chlamydia T-cell
immunoproteome. In that study, mouse MHC class II-bound
Figure 5 Vaginal loads of C. trachomatis. Chlamydial load in CAF01 controls (n=5), Hirep1+CTH93/CAF01 (n=10)- and UV-SvD/CAF01 (n=4)-immunized
pigs at day 3 pi was measured in vaginal swabs by (a) qPCR (16S rRNA) and (b) swab culturing in McCoy cells. In qPCR, each dot represents the mean of
triplicates for each pig. In swab culturing, each dot represents one well for each pig. Lines indicate the medians. Statistical difference was calculated using
the Kruskal-Wallis test followed by Dunn’s multiple comparisons test, *Po0.05.
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C. trachomatis peptides were identiﬁed by proteomics and they
identiﬁed a peptide, IFDTTTLNPTIAGAGDVK, which is covered in
the highly recognized peptide 30 from SvD and SvE used in the
present study. Consequently, in line with our observations, this
conﬁrms that this region is an important target for vaccine-induced
T cells.
Very few MOMP T-cell epitopes were induced in the UV-SvD/
CAF01 group, and epitopes recognized were primarily situated within
the constant sequences. This is in line with epitope mapping in
C. trachomatis-infected humans, in which T-cell epitopes of MOMP
are mainly located in the CSs,38,41 although also few T-cell epitopes
exist in the VDs.42
In Hirep1+CTH93/CAF01-immunized pigs, B-cell epitope mapping
in MOMP revealed high and frequent antibody recognition of the
variable domains and adjacent sequences; in particular, VD3 and
VD4 of SvD, and SvE- and SvF-speciﬁc sequences of VD4. Sera
from Hirep1+CTH93/CAF01-immunized pigs recognized Sv-speciﬁc
peptides of SvD, SvE and SvF, all surrounding peptide 30 containing
the conserved neutralizing epitope TLNPTIAG.10,43 In comparison,
the B-cell recognition in UV-SvD/CAF01-immunized pigs showed a
narrower epitope pattern, with fewer epitopes recognized, however,
still including peptide 30.
The Hirep1+CTH93/CAF01 vaccine induced strong neutralizing
antibodies consistently in all animals and sera neutralized both SvD
and SvF infection, which conﬁrms our previous ﬁndings in mice29 and
validates the vaccine for future testing in clinical trials. Also, the
UV-SvD/CAF01 vaccine induced neutralizing antibodies in line with
previously published studies,19,20 but the levels were varying with
ranges from not neutralizing to highly neutralizing within the group.
Although the UV-SvD/CAF01 group did also recognize peptide 30
encompassing the neutralizing TLNPTIAG epitope, we cannot exclude
that other surface proteins may also be involved in induction of
neutralizing antibodies, such as PorB44 and PmpD45 or even con-
formational epitopes in MOMP. Although with neutralizing potential,
antibodies induced by whole-cell vaccines13 and derivatives thereof,
that is, puriﬁed native MOMP, have been shown to promote
homotypic immunity in NHPs,46 an obstacle that is overcome by
the use of recombinant Hirep1 subunit vaccine.
Figure 6 CMI responses post infection. PBMC were stimulated (days 0 and 7 pi) with CTH93 peptide pools (MOMP SvD, CT043 and CT414aa605-840),
Hirep1 peptide pool and UV-SvD. (a) Infected controls (n=5), (b) Hirep1+CTH93/CAF01-immunized pigs (n=10) and (c) UV-SvD/CAF01-immunized pigs
(n=4). For each pig, the mean IFN-γ value of triplicate wells is shown. The box indicates the 25th and the 75th percentile within the group, the horizontal
line within a box represents the median, whiskers indicate min to max values. Statistical difference was calculated using the Wilcoxon’s matched-pairs rank
test, *Po0.05.
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Deep vaginal challenge established an infection that resolved
relatively fast and although we observed shedding up to day 12 pi,
the levels were very low and no differences between groups were found
after day 3 pi (data not shown). Nevertheless, at the very onset on
infection (day 3 pi), we did observe protection in both the Hirep1
+CTH93 and UV-SvD groups (Figure 5). Given the time point and
the neutralizing capacity of sera in both groups, this protection is likely
mediated by, at least in part, antibodies. This would also be in line
with our previous studies in mice where we observe signiﬁcant control
of bacteria at the early time point (day 3 pi).29 Interestingly, we ﬁnd
that Hirep1+CTH93/CAF01-vaccinated pigs mount a signiﬁcant T-cell
recall response directed at peptides representing CT414 and especially
Hirep1 indicating that this region is not only a target for antibodies
but also for T cells during the infection.
In non-vaccinated controls, the infection induced a T-cell response
against UV-SvD. The UV-SvD/CAF01 group had a recall T-cell
response against UV-SvD, whereas responses against Hirep1 and
CTH93 components were not boosted. In Hirep1+CTH93/CAF01-
immunized pigs, CMI responses against Uv-SvD, Hirep1 and
CT414aa605-840 were signiﬁcantly increased, demonstrating a recall
response against both Hirep1 and CTH93 components (Figure 6).
This indicates that although the protective efﬁcacy of the Hirep1
+CTH93/CAF01 vaccine and the UV-SvD/CAF01 is equal, the antigen
speciﬁcity behind this protection might be different.
In conclusion, evaluation of Hirep1+CTH93/CAF01 vaccination in
pigs demonstrates a highly immunogenic vaccine with uniform
patterns of T- and B-cell epitopes against vaccine components,
including high and frequent recognition of SvE- and SvF-speciﬁc
sequences. Hirep1+CTH93/CAF01 vaccination generates both neu-
tralizing antibodies against SvD and SvF and protective immune
responses comparable with the UV-SvD/CAF01 vaccine, but the
hybrid vaccine would be a safer alternative, excluding antigens
associated with immunopathology.
METHODS
Ethics statement
The experimental procedures were approved by the Danish Animal
Experiments Inspectorate of the Danish Veterinary and Food Administration,
license no: 2008/561− 1581.
Chlamydia trachomatis
C. trachomatis SvD (Trachoma type D strain UW-3/Cx, ATCC VR-885) was
propagated in Hela cells (Human epithelial cell line, Hela 229, ATCC CCL-2.1),
and chlamydial elementary bodies (EBs) were harvested and puriﬁed as
described by Olsen et al.37 with few modiﬁcations: Hela cells were cultured
in six-well plates and were infected with 1.5 C. trachomatis SvD IFUs per Hela
cell. Instead of diethylaminoethyl-dextran treatment, the cells were centrifuged
at 750 g for 1 h. For use as vaccine antigen, the chlamydial EBs were inactivated
by exposure to ultraviolet light emission as described,47 and the inactivation
step was conﬁrmed by culture in Hela cells. Finally, the content of protein was
quantiﬁed by the bicinchoninic acid assay, as described in the Micro BCA
Protein Assay Kit (cat no 23235, Thermo Scientiﬁc, Rockford, IL, USA). For use
as the challenge infection, the puriﬁed chlamydial EBs were IFU quantiﬁed in
Hela cells.
Chlamydia trachomatis antigens
Recombinant fusion proteins CTH93 and Hirep1 were produced as follows;
CTH93 was designed as a fusion protein of CT043 (full length), CT414aa605-840
and MOMP SvDaa34-371 (Supplementary Figure 1) with an added N-terminal
histidine tag, all sequences obtained from the original annotation published in
the study by Stephens et al.48 The Hirep1 hybrid vaccine was composed of VD4
regions from SvD, SvE and SvF, including residues in the constant regions
adjacent to VD4.29 Synthetic DNA constructs were codon-optimized for
expression in Escherichia coli followed by insertion into the pJexpress 411
vector (DNA2.0). To avoid disulﬁde bridge formation during recombinant
production, cysteines in MOMP were exchanged systematically with serines.
Puriﬁcation was carried out essentially as described by Olsen et al.49
Vaccines
The hybride antigens were diluted in 1ml sterile Tris buffer (10mM, pH 7.4)
and were mixed by vortexing with 1ml cationic liposomic adjuvant CAF01
(500 μg of glycolipid trehalose 6,6′-dibehenate and 2500 μg of dimethyldiocta-
decylammonium bromide) and sucrose into a total volume of 2 ml isotonic
(9% sucrose) vaccine.
Animals
Nineteen, sexually mature, female Göttingen minipigs were purchased from
Ellegaard Göttingen Minipigs A/S, Dalmose, Denmark, which is breeding
microbiologically well-deﬁned minipigs in a barrier unit, in which the herds
are health-monitored twice a year, following FELASA recommendations. At
delivery, the minipigs were 5–6 months old. The pigs were housed in groups of
four to six, fed with standard minipig diet twice a day and water ad libitum. The
study was carried out in a laboratory animal isolation facility at University of
Copenhagen.
Design of study
The 19 female minipigs were randomly divided into four groups immunized
with either CAF01, 10 μg Hirep1+CTH93/CAF01, 100 μg Hirep1+CTH93/
CAF01 or 125 μg UV-SvD/CAF01; see Table 1. The vaccines were administered
twice intramuscularly in the neck muscles, week 0 and week 3. Pigs immunized
with CAF01 and UV-SvD/CAF01 are also included in another study focusing
on immunohistochemical analysis supported by immunological data and
chlamydial shedding. To estrus synchronize the pigs, they were treated orally
with 20mg progestagens (Regumate Equine, MSD Animal Health, Ballerup,
Denmark) for 18 days and 6 or 8 days after cessation of treatment, they went
into estrus with proximity of a teaser boar. The pigs were sedated with
Zoletil mixture (2.5mgml− 1 tiletamine, 2.5mgml− 1 zolazepam, 20mgml− 1
xylazine, 100mgml− 1 ketamin, 10mgml− 1 butorphanol) and inoculated
intravaginally at the most cranial part of the vagina with 3.9× 109 IFUs of
C. trachomatis SvD diluted in 5ml SPG (0.2 M sucrose, 20mM sodium
phosphate and 5mM glutamic acid buffer) with an insemination catheter
(Osiris, cat no 902011, E-Vet, Haderslev, Denmark). The pigs were inoculated
30 or 32 days after the second immunization and were killed at day 12 pi by
deep anesthesia followed by exsanguination. Rectal temperature and clinical
signs were recorded after each vaccination day and on a daily basis after the
challenge. Blood samples and vaginal swabs were taken at week 0 and 3 and at
days 0, 7 and 12 pi; vaginal swabs were additionally taken at days 3 and 5 pi.
For collection of sera, unstabilized blood was centrifuged at 2400 g for 15min,
and serum was transferred into new tubes and kept at 20 °C until analysis.
Vaginal sampling
Before vaginal sampling, the pigs were anesthetized in Zoletil mixture, and the
outer vulva was rinsed in water and 70% ethanol. By using a speculum, a swab
was introduced into the deeper part of the vagina, close to the cervix, where the
swab was rolled clockwise twice along the vaginal wall. The swabs were kept in
tubes containing 1ml SPG. Three autoclaved glass beads were added to each
swab sample, followed by whirl mixing for 2 min. The samples were kept at
− 80 °C until further analysis. On day 3 pi, the swabs were cultured fresh as
described below.
Detection of chlamydial load by culturing
The protocol for detection of chlamydial load in vaginal swabs was modiﬁed
from the protocol of Hansen et al.50 Brieﬂy, McCoy cells (murine ﬁbroblast
cell line, ATCC CRL-1696) were cultured in infection media (RPMI 1640
supplemented with 5% fetal calf serum, 10mM HEPES, 1% (vol/vol) non-
essential amino acids for MEM Eagle, 2 mM L-glutamine, 1mM pyrovate,
10 μgml− 1 gentamicin, 70 μM mercaptoethanol) in 48-well plates for 24 h.
C. trachomatis bacteria were detected with sera from MOMP and C. trachomatis
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heat shock protein 60-immunized rabbits followed by staining with 4 μg ml− 1
Alexa Flour 488-labeled goat-anti rabbit antibody (Cat no: A11008, Life
Technologies, Paisley, UK), and McCoy cells were stained with propidium
iodide. At least 20 (×40) ﬁelds were counted for IFU in each well using an
Olympus IX71 ﬂuorescence microscope (Ballerup, Denmark), and the no of
IFUs per swab was calculated.
Detection of chlamydial load by quantitative PCR
DNA extraction from the vaginal swab samples was performed with Chelex 100
(Bio-Rad, Life Science, Copenhagen, Denmark). One hundred microliters of
the swab material were mixed with 300 μl of a 20% Chelex solution in TE
buffer (T9285, Sigma Aldrich, Copenhagen, Denmark), vortexed for 60 s and
incubated at 96 °C for 10min. The sample was then centrifuged for 10min at
17 500 g and 4 °C and hereafter triplicates of 5 μl of the supernatant was used
for PCR. Real-time qPCR detection of C. trachomatis in the vaginal swab
samples was performed by detection of the 16S rRNA gene. An internal
control (IC) was run in all samples to detect possible inhibition of the PCR.
The IC primers were bought from TAG Copenhagen A/S (Copenhagen,
Denmark): IC-F 5′ACCGCTCAGGCATTTGCT-3′ and IC-R 5′CCGGGA
CGTATCATGCT3′. The remaining primers and probes were bought from
Applied Biosystems: Ct 16s-F GGATCTTCGGACCTTTCGGT; Ct 16s-R
AATCTCTCAATCCGCCTAGACA; Ct 16s-probe FAM-AAGGGAGAGTCT
ATGTGATAT–MGBNFQ, IC-probe NED-CCTTCGTGATATCGGACGTTGG
CTG- MGBNFQ. The assay was performed with: Perfecta qPCR SuperMix
(UNG, low ROX, 95066-02K (2000 rx), Quantum Biosciences). The samples
were run on a StepOne Real-time PCR instrument (Applied Biosystems) and
the instrument was programmed to run 2min at 95 °C and 40 cycles of
denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 1min. The
Ct cutoff was determined to be 37, hence Ct values greater than 37 were
considered as nonsense.
Measurement of antigen-speciﬁc antibodies in serum and in
vaginal swabs
Determination of antigen-speciﬁc antibodies in serum and vaginal swabs was
carried out by indirect ELISA. Ninety-six-well plates were coated overnight with
0.4 μg of UV-SvD (using Polysorp plates, NUNC, Roskilde, Denmark) and
0.1 μg Hirep1, 0.1 μg CTH93 or 0.1 μg MOMP SvD peptide 30 (using Maxisorp
plates, NUNC) in bicarbonate/carbonate buffer (pH 9.6) per well. Study
samples were added in duplicates in serial dilutions and incubated overnight.
An internal standard was used on each plate to correct for plate-to-plate
variation. Sample antibodies were detected with horse radish peroxidase-
conjugated goat-anti pig IgG secondary antibodies (1:10.000, AAI41P, Serotec,
Oxford, UK). The wells were visualized with TMB PLUS substrate (Kem-En-
Tec, Taastrup, Denmark) and 0.5 M sulfuric acid. The plates were read at the
wavelength of 450 nm with correction at 650 nm. To compensate for plate-to-
plate variation, the log-transformed OD mean of the titrated internal standard
on each plate was correlated with the log-transformed mean of the internal
standard on all plates analyzed simultaneously, resulting in a regression
equation for each plate. For each plate, the sample OD values were transformed
according to the regression equation. After that, the end point titers
were calculated as the highest sample dilution before reaching the cutoff.
The cutoff value was calculated for each individual antigen as the mean of the
lowest dilution from all week 0 samples added to two times the standard
deviation.
B-cell epitope mapping was performed as described for detection of
antibodies with few modiﬁcations: 96-well Maxisorp plates were coated
overnight with duplicates of overlapping peptides (20-mer with 10 aa overlap)
(5 μg ml− 1) covering vaccine antigens (MOMP, Hirep1, CT043 and
CT414aa605-840). The peptides are listed in Supplementary Tables 1. After the
blocking and washing steps, sera drawn after two immunizations (week 7) were
diluted (1:200) and added to the wells and serial dilutions of an internal
standard were used to minimize plate-to-plate variation, and the plates were
incubated overnight and developed as described. The results were given as OD
values.
Measurement of neutralizing antibodies in vitro
The neutralizing capacity of the serum antibodies were investigated by an
in vitro assay, as described.32 HaK cells (Syrian Golden hamster epithelial cell
line, ATCC CCL-15) were cultured in infection media (as described for
culturing swabs in McCoy cells) in Nunclon sterile 96-well plates (Cat no:
167008, Thermo Scientiﬁc). C. trachomatis SvD or SvF EBs were incubated for
30min at 37 °C with titrations of heat-inactivated sera from immunized and
naïve pigs. EB-sera mixtures were added to the conﬂuent HaK cell layers in
duplicates, and SPG and pooled naïve sera from controls were added on each
plate as controls. After 2 h of incubation at 35 °C, the EB-sera mix was removed
from the wells, and new infection media with 0.5% glucose and 1 μgml− 1
cycloheximide were added, followed by incubation at 37 °C for 42 h. Chlamydia
bacteria were detected with sera from CT043 and cHsp60-immunized
rabbits followed by staining with 4 μgml− 1 Alexa Flour 488-labeled goat-anti
rabbit antibody (Cat no: A11008, Life Technologies), and HaK cells were
stained with propidium iodide. At least 20 ﬁelds (×40) were counted for IFUs
in each well using an Olympus IX71 ﬂuorescence microscope, and for each
dilution, the % inhibition of the sample related to the pooled naïve control
sera on the same plate was calculated by the formula: Neutralization
%= 100—((Mean IFUs of duplicate wells/mean IFUs of pooled sera from
naïve controls) × 100).
In vitro stimulation of PBMCs
PBMCs were isolated by density gradient centrifugation on Lympholyte-
Mammal medium (1.086 g cm− 3 at 22 °C, Cedarlane Labs, Skanderborg,
Denmark) and cultured in RPMI-1640 with 5× 10− 5 M 2-mercaptoethanol,
1 mM glutamine, 1% pyruvate, 1% penicillin-streptomycin, 1% HEPES and
10% fetal calf serum (Invitrogen, Taastrup, Denmark), with 2× 105 cells/well
were added in Nunclon microtiter plates (NUNC). The cells were stimulated in
triplicates with UV-SvD, Hirep1, CTH93, CT043, CT414aa605-840 and MOMP
in 10 μg ml− 1. Synthetic peptides (20-mer) with 10 aa overlap covering CT043,
CT414aa605-840, MOMP and Hirep1 were purchased from (Genscript,
Piscataway, NJ, USA) and used for stimulation as pools (5 μgml− 1 of each
peptide in the peptide pools) or as individual peptides (5 μgml− 1). The
peptides are listed in Supplementary Tables 1. Wells with medium alone and
with Staphylococcal enterotoxin B (1 μg ml− 1) were included as negative and
positive control, respectively. After 3 days of incubation at 37 °C with 5% CO2,
cell culture supernatants were harvested and stored at − 20 °C.
Determination of IFN-γ in cell culture supernatants by ELISA
The levels of IFN-γ in cell culture supernatants were determined by a
monoclonal ELISA using anti-porcine IFN-γ monoclonal antibody clone
P2F6 (MP700, Thermo Scientiﬁc) and biotin-conjugated mouse anti-pig
IFN-γ monoclonal antibody clone P2C11 (559958, BD Pharmingen, San
Diego, CA, USA), as described by Riber et al.51 The plates were developed
with TMB Plus (Kem-En-Tec) in the dark, and the reaction was stopped by
adding 0.5 M sulfuric acid. The OD was read at wavelength 450 nm with
correction at 650 nm. From the standards, a double logarithmic curve was
constructed to quantify the levels of IFN-γ in the samples.
Statistics
All statistical analyses were performed using Graph Pad Prism software.
To compare time-dependent differences within a group, we used the paired,
non-parametric Friedman test followed by Dunn multiple comparisons test.
Comparison of difference between selected groups at the same time point was
performed by the non-parametric Kruskal-Wallis test followed by Dunn
multiple comparisons test. Evaluation of variance within a group at two
timepoints was carried out by Wilcoxon's matched-pairs rank test. Signiﬁcant
difference was deﬁned as Po0.05 (*Po0.05, **Po0.01, ***Po0.001).
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